SEARCH

SEARCH BY CITATION

References

  • 1
    Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Eng J Med 1976;295:913916.
  • 2
    Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109:7177.
  • 3
    Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest, in press.
  • 4
    Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011;20:246259.
  • 5
    Weigert O, Weinstock DM. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood 2012;120:25532561.
  • 6
    Henry L, Carillo S, Jourdan E, et al. Association of essential thrombocythemia and chronic lymphocytic leukemia: Absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol 2007;82:500501.
  • 7
    Hussein K, Brakensiek K, Ballmaier M, et al.Bock O, Kreipe H. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006;77:539541.
  • 8
    Stijnis C, Kroes WG, Balkassmi S, et al. No evidence for JAK2 mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Acta Haematol 2012;128:183186.
  • 9
    Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006;108:13771380.
  • 10
    Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:3238.
  • 11
    Pardanani A, Lasho TL, Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007;25:23582362.
  • 12
    Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol 2005;42:266273.
  • 13
    Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: A study of 1,915 patients. Haematologica 2011;96:454458.
  • 14
    Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009;18:20682073.